We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 09, 2021

Interferon Beta-1a Plus Remdesivir Did Not Benefit Hospitalized Adults With COVID-19

The Lancet Respiratory Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Respiratory Medicine
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial
Lancet Respir Med 2021 Oct 18;[EPub Ahead of Print], AC Kalil, AK Mehta, TF Patterson, N Erdmann, CA Gomez, MK Jain, CR Wolfe, GM Ruiz-Palacios, S Kline, J Regalado Pineda, AF Luetkemeyer, MS Harkins, PEH Jackson, NM Iovine, VF Tapson, MD Oh, JA Whitaker, RA Mularski, CI Paules, D Ince, J Takasaki, DA Sweeney, U Sandkovsky, DL Wyles, E Hohmann, KA Grimes, R Grossberg, M Laguio-Vila, AA Lambert, D Lopez de Castilla, E Kim, L Larson, CR Wan, JJ Traenkner, PO Ponce, JE Patterson, PA Goepfert, TA Sofarelli, S Mocherla, ER Ko, A Ponce de Leon, SB Doernberg, RL Atmar, RC Maves, F Dangond, J Ferreira, M Green, M Makowski, T Bonnett, T Beresnev, V Ghazaryan, W Dempsey, SU Nayak, L Dodd, KM Tomashek, JH Beigel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading